Condition: Sickle Cell Disease · Sponsor: Novartis Pharmaceuticals
This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| University Of Alabama | Birmingham, Alabama, United States | Recruiting |
| Childrens National Hospital | Washington D.C., District of Columbia, United States | Active Not Recruiting |
| Augusta University Georgia | Augusta, Georgia, United States | Recruiting |
| East Carolina University | Greenville, North Carolina, United States | Completed |
| East Carolina University | Greenville, North Carolina, United States | Completed |
| Childrens Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Active Not Recruiting |
| Cook Childrens Medical Center | Fort Worth, Texas, United States | Completed |
| Novartis Investigative Site | Brussels, Belgium | Completed |
| Novartis Investigative Site | Laken, Belgium | Active Not Recruiting |
| Novartis Investigative Site | Liège, Belgium | Active Not Recruiting |
| Novartis Investigative Site | Salvador, Estado de Bahia, Brazil | Active Not Recruiting |
| Novartis Investigative Site | Ribeirão Preto, São Paulo, Brazil | Active Not Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04657822